Image pharmaphorum Editor R&D Living with LHON: Adapting to sight loss at 15 years old When faced with a devastating diagnosis, a family has two choices – to give up or make it their mission to adapt and carry on. R&D How pharma can support doctors who treat rare diseases Where do doctors see patients with rare diseases, how do they keep up with treatment advances and what can pharmaceutical companies do to help? R&D The patient perspective on advocacy Growing up with the shadow of Huntington’s disease (HD) means Seth Rotberg understands the importance of peer support and credible information. R&D Strength in numbers: Because having a rare disease isn’t rar... Rare doesn’t mean insignificant – in fact more people live with a rare disease than with cancer and AIDS combined. Load more results
R&D Living with LHON: Adapting to sight loss at 15 years old When faced with a devastating diagnosis, a family has two choices – to give up or make it their mission to adapt and carry on.
R&D How pharma can support doctors who treat rare diseases Where do doctors see patients with rare diseases, how do they keep up with treatment advances and what can pharmaceutical companies do to help?
R&D The patient perspective on advocacy Growing up with the shadow of Huntington’s disease (HD) means Seth Rotberg understands the importance of peer support and credible information.
R&D Strength in numbers: Because having a rare disease isn’t rar... Rare doesn’t mean insignificant – in fact more people live with a rare disease than with cancer and AIDS combined.
News FDA starts review of Regeneron's drug for rare disease FOP Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
